Pharmaco

Biotec Pharmacon Announces Preliminary Results from the Sloan-Kettering Clinical Study

TROMSØ, Norway, June 29, 2007-Preliminary results fromthe immunotherapeutic cancer study at Memorial Sloan-KetteringCancer Center show a very good safety profile for SBG. Furthermore,encouraging responses on cancer development have been observedamong several patients that have been treated with SBG incombination with the monoclonal antibody against neuroblastoma. In line wit...

Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 27, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) today announced positive resultsfrom a recently-completed multi-dose pharmacokinetic study ofvaginally-administered lidocaine, which the Company is developingto prevent and treat dysmenorrhea. This 42-subject study was designed to provide data on bloodlevels associated with the Company's bioadhesiv...

Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin

VIENNA, Va., June 20, 2007 /PRNewswire/ -- Modigene Inc., aNevada corporation today announced the successful completion ofpharmacokinetic and pharmacodynamic pre-clinical experiments forlong-acting human growth hormone, long-acting interferon beta andlong-acting erythropoietin. Modigene's pharmacodynamic and pharmacokinetic pre-clinicalexperiments demonstrated superb durability of...

Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics

Trophos Describes Identification, Characterization and BroadNeuroprotective Properties of TRO19622 in Journal of Pharmacologyand Experimental Therapeutics Neurodegenerative Disease Specialists Publish Details of a NovelDrug Candidate for ALS That Targets Mitochondrial Proteins MARSEILLE, June 19th, 2007 - Trophos SA, a biopharmaceuticalcompany specializing in the discovery an...

Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 12, 2007 - GeronCorporation's (Nasdaq:GERN) telomerase inhibitor cancer drug,GRN163L, has demonstrated good pharmacokinetics and tolerability inits ongoing Phase I/II trial involving patients with chroniclymphocytic leukemia (CLL), according to data presented today byAlan Colowick, M.D., M.P.H., the company's president, oncology, atthe Pan Pacific Ly...

Sosei Announces Successful Completion of AD 923 Pharmacokinetic Study in the USA

TOKYO, May 22, 2007 /PRNewswire-FirstCall/ -- Sosei GroupCorporation , a biopharmaceutical company, today announces thesuccessful completion of a study of its fentanyl sublingual spray(AD 923), an opioid analgesic for the treatment of cancerbreakthrough pain. This was a pharmacokinetic Phase I single centre, open-label,single dose, cross-over, randomised study of AD 923 versus Acti...

Alpharma Presents Positive Pharmacokinetic Study Results of Its Investigational Abuse-Deterrent, Extended-Release Opioid

BRIDGEWATER, N.J., May 03, 2007 /PRNewswire-FirstCall/ --Alpharma Inc. , a leading global specialty pharmaceutical companythrough its Pharmaceuticals Division, this week presented positiveresults of a pharmacokinetic study of its investigationalabuse-deterrent, extended-release opioid at the 26th annualscientific meeting of the American Pain Society in Washington, D.C.The data demonstrat...

ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)

Results Indicate Bioequivalent Pharmacokinetics With Reduced Riskof Hypersensitivity Reactions With ANX-514 SAN DIEGO, April 25, 2007 /PRNewswire-FirstCall/ -- ADVENTRXPharmaceuticals, Inc. , a biopharmaceutical research anddevelopment company focused on commercializing proprietary productcandidates for the treatment of cancer and infectious diseases,today announced positive results from...

New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2007 - Biogen Idec Inc.(NASDAQ: BIIB) announced today that one-year data presented at theAcademy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting showthat AVONEX(R) (Interferon beta-1a) is a cost-effective therapy inmultiple sclerosis (MS) when compared to other interferon betatreatments. Using a comprehensive analysis of medical and pharmacyc...

First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

KANSAS CITY, Mo.--(BUSINESS WIRE)--Apr 11, 2007 - A comparison ofthe long-term economic outcomes of four immunomodulatory drugtherapies combined with symptom management versus symptommanagement alone revealed that COPAXONE(R) (glatiramer acetateinjection) was the most cost-effective treatment strategy forrelapsing-remitting multiple sclerosis (RRMS). The study providesthe first pharmacoecon...

Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial

PS433540 Shown to Be Well Tolerated and Potentially Suited for OnceDaily Administration PRINCETON, N.J., April 10, 2007 /PRNewswire-FirstCall/ --Pharmacopeia , an innovator in the discovery and development ofnovel small molecule therapeutics, today announced positive resultsfrom the initial Phase 1 clinical trial of PS433540, the company'slead internal product candidate for the treatment...